Pfizer Poised to Beat the Street Again This Quarter
May, 03rd 07:38
Pfizer’s earnings are projected to rise by 8% to 55 cents per share while revenue is expected to increase by 10% to $12 billion. The company has aggressively cut costs, expanded its products pipeline and signed new licensing deals. All this adds up towards meeting or beating expectations. On the H1 chart, the stock last traded at 32.69. DI+ is above the DI-, suggesting continual gains, although the rally has not been very strong yet with the ADX under 20.